Covid-19 vaccine booster

From Aaushi
Jump to navigation Jump to search

Indications

  • immunocompromised individuals
  • adults, adolescents 12 & up (5 months after 2nd dose) (Pfizer or Moderna)[40]
    • mix & match equally safe & effective[46]
  • during Omicron predominance, COVID-19 hospitalization rates in Los Angeles County among unvaccinated persons were 23.0 times those of fully vaccinated persons with a booster, & 5.3 times those among fully vaccinated persons without a booster[45]
  • previously unvaccinated individuals will be eligible for a single dose of bivalent Moderna or Pfizer Covid-19 vaccine[82]
    • they will then be considered fully vaccinated (after 2 weeks) & not eligible for a Covid-19 vaccine booster[82]

Adverse effects

Notes

WHO did not support booster vaccinations early in the pandemic

  • richer countries should focus on ramping up vaccine supply to billions who are still waiting for their first dose[4][5]
  • solely for the purpose of managing a pandemic (independent of alleviating death & suffering in low & lower-middle income countries where < 15% of people are vaccinated), preventing the emergence of variants is far better managed by vaccinating the underserved unvaccinated than to vaccinate the vaccinated[4][22]
  • Covid-19 is likely here to stay as SARS-CoV2 continues to mutate in unvaccinated countries across the world & previous hopes of eradicating it diminish (WHO)[16]

* see pandemic management

2 dose mRNA vaccines produce strong protection

  • multiple studies show that 2 dose mRNA vaccines provide strong protection against severe disease (95% against hospitalization)[5]
  • data from the Israeli Ministry of Health suggests protection against severe disease is nearly 92% for people < 50 years & 85% for those > 50 years (without booster)
  • overall effectiveness of Pfizer vaccine decreases from 96% to 84% after 6 months[9]
  • antibody titer decline faster in cipients of the Pfzer vaccine than in COVID-19 survivors[11]
    • antibody titers decline by up to 40% per month in vaccinated persons, vs < 5% per month in Covid-19 convalescents
    • at 6 months, ~84% of vaccine recipients still have detectable antibody titers, whereas ~90% of Covid-19 convalescents still have detectable antibodies titers after 9 months[11]
    • a 3rd dose of Pfizer vaccine increases immune response 11 times higher than after the 2nd dose in older patients 65-85 years of age[9] (12 people studied)
    • a 3rd dose of Pfizer vaccine increases protection against Covid-19 infection 4-fold after 10 days in adults > 60 years according to Israeli Health Ministry[10]
  • early supporting evidence for booster largely from Israel for Pfizer vaccine
  • 4th Pfizer vaccine of marginal benefit to Israeli healthcare workers[47]
  • vaccine effectiveness generally decreases over time against SARS-CoV-2 infections, hospitalizations, & mortality[79]

breakthrough infections likely due to Delta variant, not waning immunity

in immunocompromised patients

Covid-19 vaccine booster marketing

  • Pfizer vaccine booster does substantially increase serum anti-spike protein antibody levels[35]
  • Moderna seeks FDA-approval for Covid-19 vaccine booster September 2021[14]
  • a Pfizer BNT162b2 vaccine booster among fully vaccinated Israeli citizens >= 60 years at least 5 months after 2nd dose had 11 fold decrease in risk of confirmed Covid-19 infection & > 19-fold decrease in risk of severe disease[15]
    • methods include 1,144,690 individuals >= 60 years followed between July 30 & August 22, 2021 & adjusting for possible confounding factors
    • reported follow-up period for that trial only went to 25 days post vaccination[15]
  • a 2nd dose of J&J Ad26.COV2.S vaccine induces high antibody levels[2]
  • Covid-19 vaccine makers plan for annual boosters[37]
  • Omicron variant could make it more likely that people will need a 4th Covid-19 vaccine earlier than expected[39]

boosters & Omicron

Federal Agencies on Covid-19 vaccine booster

  • FDA & CDC joint statements: (historical)
    • Covid-19 vaccine booster not needed (July 8, 2021)[8]
    • Covid-19 vaccine booster would be offered Sept 20, 2021 (August 18, 2021)[8]
      • 2 high-level officials in the FDA's Office of Vaccines Research & Review resigned reportedly because they were angry that the Biden administration was making decisions that should be left up to that agency[13]
  • FDA advisory panel voted unanimously on Sept 17, 2021 to recommend a 3rd dose of Pfizer's mRNA COVID-19 vaccine for elderly >=65 & those at high risk for severe outcomes[19][26]
    • the FDA advisory panel voted 16-2 against a 3rd dose of Pfizer vaccine for Americans >= 16 years[26]
    • CDC confirms recommendation of a 3rd dose of Pfizer's mRNA COVID-19 vaccine for elderly >=65 & those at high risk for severe outcomes, but not for healthcare or other frontline workers[28]
  • FDA advisory panel VRBPAC[31] & CDC[34] recommends approval of Moderna booster
    • dose 50 ug
    • adults ages >= 65 years
    • younger adults with high-risk medical conditions
    • high risk of occupational or institutional exposure
  • FDA advisory panel VRBPAC recommends a booster dose of Johnson & Johnson's COVID-19 vaccine for all individuals who received the single-dose vaccine[32]
  • FDA approves Johnson & Johnson's vaccine booster[34]
    • to be given >= 2 months after the initial dose
    • safe for people who got the Johnson & Johnson vaccine follow up with a dose of an mRNA vaccine from Pfizer or Moderna[33]
  • FDA approves 2nd booster dose of Pfizer or Moderna's mRNA COVID-19 vaccine for adults ages >= 50 years, & immunocompromised persons[48]*
  • FDA approves 2nd booster dose of Pfizer or Moderna's mRNA COVID-19 vaccine for adults >= 65 years or immunocompromised persons[81]
  • large study supports the recommendation for a second Pfizer booster in long-term care residents June 2022[59]
    • senior author with signficant financial ties to Pfizer
  • study in Isreal among healthcare workers Jan 2-Jan 31, 2022 reports 4th dose of Pfizer vaccine (given on Jan 2) reduced infection from 19.8% to 6.9%[60]

* immunocompromised people will receive 5 doses of Covid-19 mRNA vaccine in total: a 3-dose primary series, & 2 boosters[48]

Pfizer Covid-19 vaccine booster in Israel

  • Pfizer Covid-19 vaccine booster decreased risk of severe disease by a factor of 18 in persons > 60 years and 22 in younger persons
  • a 4th dose of Pfizer BNT162b2 vaccine effectiveness against infection peaked at 65% during week 3 after vaccination but declined to 22% by week 10
    • 72% effective in preventing severe disease for >= 10 weeks[56]

More general terms

References

  1. Pradhan R 'We Sent a Terrible Message': : Scientists Say Biden Jumped the Gun With Vaccine Booster Plan. Kaiser Health News. August 20, 2021 https://khn.org/news/article/covid-vaccine-boosters-science-biden-plan-jumped-gun/
  2. 2.0 2.1 Zimmer C Second Dose of J. & J. Vaccine Gives Strong Boost, Company Reports. New York Times. August 24, 2021 (via Doximity) https://www.doximity.com/articles/d5769040-5949-4336-9d7c-638c22702d27
  3. Armour S, Hopkins JS Biden Administration Likely to Approve Covid-19 Boosters at Six Months. Pfizer, BioNTech have requested clearance for Covid-19 vaccine boosters that an official said could be administered six months after previous dose. Wall Street Journal. August 26, 2021 https://www.wsj.com/articles/biden-administration-plans-covid-19-vaccine-boosters-at-six-months-instead-of-eight-11629919356
  4. 4.0 4.1 4.2 Nature Editorial. August 17, 2021 The WHO is right to call a temporary halt to COVID vaccine boosters. Nature 596, 317 (2021) https://www.nature.com/articles/d41586-021-02219-w
    Mishra M, Nadeem D WHO calls for halting COVID-19 vaccine boosters in favor of unvaccinated. Reuters. August 4, 2921 https://www.reuters.com/business/healthcare-pharmaceuticals/who-calls-moratorium-covid-19-vaccine-booster-doses-until-september-end-2021-08-04/
  5. 5.0 5.1 5.2 Vogel G Unethical? Unnecessary? The COVID-19 vaccine booster debate intensifies. Science. 2020. August 27. https://www.sciencemag.org/news/2021/08/unethical-unnecessary-covid-19-vaccine-booster-debate-intensifies
  6. 6.0 6.1 Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1167-1169 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34437521 Free article. https://www.cdc.gov/mmwr/volumes/70/wr/mm7034e4.htm
  7. Prasad V Are We Jumping the Gun on COVID Boosters? Efficacy, safety, and ethical questions linger. MedPage Today. August 24, 2021 https://www.medpagetoday.com/opinion/vinay-prasad/94188
  8. 8.0 8.1 8.2 Sullivan P Pfizer to seek FDA authorization for booster of COVID-19 vaccine. The Hill. 2021. July 8 https://thehill.com/policy/healthcare/562169-pfizer-to-seek-fda-authorization-for-booster-of-covid-19-vaccine
    HHS.gov. July 8, 2021 Joint CDC and FDA Statement on Vaccine Boosters. https://www.hhs.gov/about/news/2021/07/08/joint-cdc-and-fda-statement-vaccine-boosters.html
    HHS.gov. August 18, 2021 Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots. https://www.hhs.gov/about/news/2021/08/18/joint-statement-hhs-public-health-and-medical-experts-covid-19-booster-shots.html
  9. 9.0 9.1 9.2 McNamara D Pfizer Vaccine Protection Wanes After 6 Months: Study. Medscape - Jul 28, 2021. https://www.medscape.com/viewarticle/955601
    Thomas SJ, Moreira ED Jr, Kitchin N et al Six Month Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. medRxiv. July 18, 2021 Not indexed in PubMed https://www.medrxiv.org/content/10.1101/2021.07.28.21261159v1
  10. 10.0 10.1 Reuters Israel finds COVID-19 vaccine booster significantly lowers infection risk. Reuters. August 23, 2019 https://www.reuters.com/world/middle-east/israel-finds-covid-19-vaccine-booster-significantly-lowers-infection-risk-2021-08-22/
  11. 11.0 11.1 11.2 Reuters Staff Antibodies Fade Faster After Vaccine vs Actual Infection. Medscape. August 24, 2021 https://www.medscape.com/viewarticle/957089
    Israel A, Shenhar Y, Green I et al Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. medRxiv. August 22, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34462761 Free PMC article. https://www.medrxiv.org/content/10.1101/2021.08.19.21262111v1
  12. Leonhart D The Morning. The booster-industrial complex. New York Times. August 30, 2021
  13. 13.0 13.1 Goodman B Politics or Protection? What's Behind the Push for Boosters? Medscape. September 1, 2021 https://www.medscape.com/viewarticle/958013
    Brennan Z In a major blow to vaccine efforts, senior FDA leaders stepping down Endpoints News. August 31, 2021 https://endpts.com/breaking-in-a-major-blow-to-vaccine-efforts-senior-fda-leaders-stepping-down-report/
  14. 14.0 14.1 Erman M, Maddipatla M Moderna Seeks US Authorization for COVID-19 Vaccine Booster. Medscape. September 2 2021 https://www.medscape.com/viewarticle/958068
  15. 15.0 15.1 15.2 Bar-On Y, Goldberg Y, Mandel M et al BNT162b2 vaccine booster dose protection: A nationwide study from Israel. MedRxiv. 2021. August 31. https://www.medrxiv.org/content/10.1101/2021.08.27.21262679v1
    Bar-On YM, Goldberg Y, Mandel M Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021 Sep 15. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34525275
  16. 16.0 16.1 Mendez R WHO says Covid will mutate like the flu and is likely here to stay. CNBC Health and Science. September 7, 2021. https://www.cnbc.com/2021/09/07/who-says-covid-is-here-to-stay-as-hopes-for-eradicating-the-virus-diminish.html
  17. 17.0 17.1 Crist C. Biden Administration Scaling Back Sept. 20 Booster Plan. Medscape - Sep 08, 2021. https://www.medscape.com/viewarticle/958365
  18. 18.0 18.1 Keaten J WHO chief urges halt to booster shots for rest of the year. AP News. September 8, 2021 https://apnews.com/article/business-health-coronavirus-pandemic-united-nations-world-health-organization-6384ff91c399679824311ac26e3c768a
  19. 19.0 19.1 19.2 Steenhuysen J FDA Vaccine Advisers Face Thorny Question: Are COVID-19 Boosters Needed? Medscape. September 7, 2021 https://www.medscape.com/viewarticle/958117
    Goodman B FDA Analysis Chills the Rush to Approve Boosters. Medscape. 2021 Sept 16. https://www.medscape.com/viewarticle/958906
  20. Khoury DS, Cromer D, Reynaldi A et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34002089
  21. Mandavilli A In a new review, some F.D.A. scientists and others say boosters aren't needed for the general population. New York Times. Sept. 13, 2021 https://www.nytimes.com/2021/09/13/health/covid-vaccine-booster-lancet.html Krause PR, Fleming TR, Peto R et al Considerations in boosting COVID-19 vaccine immune responses. Lancet. 2021 Sept 13 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34534516 Free PMC article https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02046-8/fulltext
  22. 22.0 22.1 Strohbehn GW, Parker WF, Tabarrok A. What's the Right Dose for COVID Boosters? FDA must demand dosing data before giving full approval. https://www.medpagetoday.com/opinion/second-opinions/94500
  23. Schaefer GO, Leland RJ, Emanuel EJ. Making Vaccines Available to Other Countries Before Offering Domestic Booster Vaccinations. JAMA. 2021;326(10):903-904 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34382999 https://jamanetwork.com/journals/jama/fullarticle/2783234
  24. New Pfizer data makes case for booster shots 6 months after primary doses ABC News. 2021. September 15 https://www.msn.com/en-us/health/medical/new-pfizer-data-makes-case-for-booster-shots-6-months-after-primary-doses/ar-AAOtkxI?li=BBnb7Kz
  25. McNamara D New Moderna Vaccine Data 'Support' Booster Shot After 8 Months. Medscape. 2021. September 15. https://www.medscape.com/viewarticle/958808
  26. 26.0 26.1 26.2 Goodman B FDA Panel Backs Pfizer's COVID Booster for 65 and Older, Those at High Risk. Medscape. September 17, 2021 https://www.medscape.com/viewarticle/958997
    Walker M FDA Panel Backs Pfizer Booster for Select Groups. Advisors overwhelmingly support authorization, but shot down full approval bid. MedPage Today September 17, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/94579
  27. Centers for Disease Control & Prevention (CDC) COVID-19 Vaccine Booster Shot. CDC Vaccines August 20, 2021 https://www.cdc.gov/coronavirus/2019-ncov/vaccines/booster-shot.html
  28. 28.0 28.1 Goodman B CDC Panel Backs Boosters for Seniors, but Not Healthcare Workers. Medscape. September 23, 2021 https://www.medscape.com/viewarticle/959389
  29. Wingrove J, Jacobs J FDA Leans Toward Authorizing Moderna Booster at a Half Dose. Bloomberg News. 2021, September 28. https://www.bloomberg.com/news/articles/2021-09-29/fda-leans-toward-authorizing-moderna-booster-at-a-half-dose
    Crist C FDA May Authorize Half-Dose Moderna Booster. Medscape. Spetember 30, 2021 https://www.medscape.com/viewarticle/960044
  30. Scott J, Richterman A, Cevik M. Covid-19 vaccination: evidence of waning immunity is overstated. BMJ 2021;374:n2320. September 23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34556464 https://www.bmj.com/content/374/bmj.n2320
  31. 31.0 31.1 Goodman B FDA Neutral on Moderna Bid for COVID Booster Ahead of Decisive Meeting. Medscape. October 12, 2021 https://www.medscape.com/viewarticle/960750
    Walker M Moderna Booster for Certain Populations Sails Through FDA Panel. All thumbs up, despite small sample size, data quality issues. MedPage Today October 14, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/95050
    Goodman B FDA Advisors Vote to Recommend Moderna Boosters. Medscape. October 14, 2021 https://www.medscape.com/viewarticle/960915
  32. 32.0 32.1 Walker M FDA Panel Endorses Booster for All J&J Recipients. Committee advises booster at least 2 months following initial Johnson & Johnson shot. MedPage Today October 15, 2021 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/95080
    Gooodman B FDA Panel Backs Second Shot for Those Who Got J&J Vaccine. Medscape. October 15, 2021 https://www.medscape.com/viewarticle/961003
  33. 33.0 33.1 Goodman B Mixing COVID Vaccine Boosters May Be Better Option: Study. Medscape. October 14, 2021 https://www.medscape.com/viewarticle/960932
    Atmar RL, Lyke KE, Deming ME et al Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report medRxiv. Octeober 13, 2021 https://www.medrxiv.org/content/10.1101/2021.10.10.21264827v1.full.pdf
  34. 34.0 34.1 34.2 Goodman B FDA Authorizes Boosters for Moderna, J&J, Allows Mix-and-Match. Medscape. October 20, 2021 https://www.medscape.com/viewarticle/961291
  35. 35.0 35.1 Eliakim-Raz N, Leibovici-Weisman Y, Stemmer A et al Antibody Titers Before and After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in Adults Aged >= 60 Years. JAMA. Published online November 5, 2021. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34739043 https://jamanetwork.com/journals/jama/fullarticle/2786096
  36. 36.0 36.1 Rottenberg Y, Grinshpun A, Ben-Dov IZ et al Assessment of Response to a Third Dose of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Patients With Solid Tumors Undergoing Active Treatment. JAMA Oncol. Published online November 23, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34812840 https://jamanetwork.com/journals/jamaoncology/fullarticle/2786532
  37. 37.0 37.1 Rubin R COVID-19 Vaccine Makers Plan for Annual Boosters, but It's Not Clear They'll Be Needed. JAMA. Published online November 24, 2021 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34817538 https://jamanetwork.com/journals/jama/fullarticle/2786818
  38. 38.0 38.1 Frellick M Risk for Severe COVID-19 and Death Plummets With Pfizer Booster. Medscape. December 8, 2021 https://www.medscape.com/viewarticle/964420
    Bar-On YM, Goldberg Y, Mandel M et al Protection against Covid-19 by BNT162b2 Booster across Age Groups. N Engl J Med. 2021, Dec 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34879188 https://www.nejm.org/doi/10.1056/NEJMoa2115926
    Arbel R, Hammerman A, Sergienko R et al BNT162b2 Vaccine Booster and Mortality Due to Covid-19 N Engl J Med. 2021, Dec 8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/34879190 https://www.nejm.org/doi/full/10.1056/NEJMoa2115624
  39. 39.0 39.1 Crist C Omicron May Require Fourth Vaccine Dose, Pfizer Says. Medscape. December 9, 2021 https://www.medscape.com/viewarticle/964505
  40. 40.0 40.1 40.2 Walker M FDA Lowers Age Range for Pfizer Booster Shot. Agency also shortens interval between primary series and boosters for ages 12 and up. MedPage Today January 3, 2022 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/96470
    AMA Morning Rounds. Jan 10, 2022 American Medical Association
  41. 41.0 41.1 Garcia-Beltran WF, St. Denis KJ, Hoelzemer A et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell 2021 Dec 23; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34995482 PMCID: PMC8733787 Free PMC article https://www.cell.com/cell/fulltext/S0092-8674(21)01496-3
  42. 42.0 42.1 Crist C At-Risk Americans Become Eligible for Fourth COVID Shot This Week. Medscape. Jan 10, 2022 https://www.medscape.com/viewarticle/966335
  43. 43.0 43.1 Accorsi EK, Britton A, Fleming-Dutra KE et al Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants. JAMA. Published online January 21, 2022. PMID: https://www.ncbi.nlm.nih.gov/pubmed/3506099 https://jamanetwork.com/journals/jama/fullarticle/2788485
  44. 44.0 44.1 Federman J Israel study: 4th vaccine shows limited results with omicron. Associated Press (AP). Jan 17, 2022 https://apnews.com/article/coronavirus-pandemic-health-middle-east-israel-5da0bbef16209e9c55e48af40248af11
  45. 45.0 45.1 Danza P, Koo TH, Haddix M et al SARS-CoV-2 Infection and Hospitalization Among Adults Aged >= 18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance - Los Angeles County, California, November 7, 2021=January 8, 2022. MMWR Morb Mortal Wkly Rep. ePub: 1 February 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35113851 https://www.cdc.gov/mmwr/volumes/71/wr/mm7105e1.htm
  46. 46.0 46.1 Atmar RL, Lyke KE, Deming ME et al. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med 2022 Jan 26; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35081293 https://www.nejm.org/doi/10.1056/NEJMoa2116414
  47. 47.0 47.1 Walker M 4th COVID Shot Offered 'Marginal' Benefit for Israeli Health Workers. Real-world data find higher antibody levels, subpar vaccine efficacy with extra dose. MedPage Today March 16, 2022 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/97706
  48. 48.0 48.1 48.2 Walker M FDA Greenlights Second COVID Booster for Select Groups. Another round of Pfizer or Moderna shots authorized for older or immunocompromised Americans. MedPage Today March 29, 2022 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/97920
  49. 49.0 49.1 49.2 Walker M Mixed Bag for Fourth Dose of Pfizer Vaccine vs Omicron. Real-world data show less infection and severity, but long-term benefit less clear. MedPage Today April 5, 2022 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/98061
    Bar-On YM, Goldberg Y, Mandel M et al Protection by a Fourth Dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022. April 5 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35381126 https://www.nejm.org/doi/full/10.1056/NEJMoa2201570
  50. 50.0 50.1 Wolfson AR, Freeman EE, Blumenthal KG Urticaria 12 Days After COVID-19 mRNA Booster Vaccination. JAMA. Published online April 14, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35420647 https://jamanetwork.com/journals/jama/fullarticle/2791317
  51. 51.0 51.1 51.2 Walker M Moderna: Bivalent COVID Booster Passes Muster. Superior immune response to authorized booster, company says. MedPage Today April 19, 2022 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/98278
    McNamara D Moderna: Data Show COVID Booster 'Potent' vs Newer Omicron Variants. Medscape. June 22, 2022 https://www.medscape.com/viewarticle/976034
  52. 52.0 52.1 Magen O, Waxman JG, Makov-Assif M et al Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. 2022. April 13 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35417631 https://www.nejm.org/doi/full/10.1056/NEJMoa2201688
    Offit PA. Covid-19 boosters - Where from here? N Engl J Med 2022 Apr 28; 386:1661; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/35417633
  53. 53.0 53.1 Walker M NIH Probes Palovid Relapses; Pandemic of the Unvaxxed No More? Musk Disses Wellbutrin. A daily roundup of news on Covid-19 and the rest of medicine. MedPage Today May 2, 2022 https://www.medpagetoday.com/infectiousdisease/covid19/98500
  54. 54.0 54.1 Ellis R Omicron Breakthrough Cases Boost Protection, Studies Say, Medscape. May 18, 2022 https://www.medscape.com/viewarticle/974194
  55. 55.0 55.1 Chappell B, Stein R Moderna says its new vaccine booster shows 'superior' response to omicron. NPR. June 8, 2022 https://www.npr.org/2022/06/08/1103659340/moderna-vaccine-booster-omicron
  56. 56.0 56.1 Gazit S et al. Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: Retrospective, test negative, case-control study. BMJ 2022 May 24; 377:e071113 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35609888 PMCID: PMC9127435 Free PMC article https://www.bmj.com/content/377/bmj-2022-071113
  57. 57.0 57.1 Rubin R COVID-19 Boosters This Fall to Include Omicron Antigen, but Questions Remain About Its Value. JAMA. Published online July 8, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35802386 https://jamanetwork.com/journals/jama/fullarticle/2794259
  58. 58.0 58.1 58.2 Twenter P Moderna's omicron-targeted vaccine nearly twice as effective against BA.4, BA.5. Becker's Hospital Review. July 11, 2022 https://www.beckershospitalreview.com/pharmacy/moderna-s-omicron-targeted-vaccine-nearly-twice-as-effective-against-ba-4-ba-5.html
  59. 59.0 59.1 Muhsen K et al. Association of receipt of the fourth BNT162b2 dose with Omicron infection and COVID-19 hospitalizations among residents of long-term care facilities. JAMA Intern Med 2022 Jun 23; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35737368 https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2793699
  60. 60.0 60.1 Cohen MJ, Oster Y, Moses AE et al Association of Receiving a Fourth Dose of the BNT162b Vaccine With SARS-CoV-2 Infection Among Health Care Workers in Israel. JAMA Netw Open. 2022;5(8):e2224657. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2794864
  61. 61.0 61.1 Cennimo DJ, Brusch JL COVID-19 Vaccines. Booster Vaccine Candidates Medscape. July 14, 2022 https://emedicine.medscape.com/article/2500139-overview
  62. 62.0 62.1 Havers FP, Patel K, Whitaker M, et al. Laboratory-Confirmed COVID-19-Associated Hospitalizations Among Adults During SARS-CoV-2 Omicron BA.2 Variant Predominance - COVID-19-Associated Hospitalization Surveillance Network, 14 States, June 20, 2021-May 31, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1085-1091 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36006841 https://www.cdc.gov/mmwr/volumes/71/wr/mm7134a3.htm
  63. 63.0 63.1 McNamara D FDA Authorizes Updated COVID Boosters to Target Newest Variants. Medscape. August 31, 2022 https://www.medscape.com/viewarticle/980027
  64. 64.0 64.1 Chalkias S et al. A bivalent Omicron-containing booster vaccine against Covid-19. N Engl J Med 2022 Sep 16; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36112399 https://www.nejm.org/doi/10.1056/NEJMoa2208343
  65. 65.0 65.1 Tseng HF, Ackerson BK, Bruxvoort KJ et el Effectiveness of mRNA-1273 against infection and COVID-19 hospitalization with SARS-CoV-2 Omicron subvariants: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. MedRxiv. Oct 1, 2022 https://www.medrxiv.org/content/10.1101/2022.09.30.22280573v1.full.pdf
  66. 66.0 66.1 Stulpin C Early data show Pfizer's omicron booster 'substantially' boosted antibodies against BA.5. Helio. Infectious Diseases. Oct 13, 2022 https://www.healio.com/news/infectious-disease/20221013/early-data-show-pfizers-omicron-booster-substantially-boosted-antibodies-against-ba5
  67. 67.0 67.1 AMA Morning Rounds. Oct 20, 2022 American Medical Association
  68. 68.0 68.1 Chin ET, Leidner D, Lamson L et al Protection against Omicron from Vaccination and Previous Infection in a Prison System. N Engl J Med 2022. Oct 26 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36286260 https://www.nejm.org/doi/full/10.1056/NEJMoa2207082
  69. 69.0 69.1 Ellis R Pfizer: Bivalent Booster Protects Against BQ.1.1 Subvariant. Medscape. Nov 22, 2022 https://www.medscape.com/viewarticle/984471
  70. 70.0 70.1 Chalkias S et al Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination. N Engl J Med. 2022. Nov 23 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36416761 https://www.nejm.org/doi/full/10.1056/NEJMc2212772
  71. 71.0 71.1 Wang Q, Iketani S, Li Z et al Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2022 Dec 14;S0092-8674(22)01531-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36580913 PMCID: PMC9747694 Free PMC article
  72. 72.0 72.1 AMA Morning Rounds. Dec 19, 2022 American Medical Association
    Edwards E Updated booster shot prevents a majority of Covid hospitalizations in older adults. New York Times. Dec 16, 2022 https://www.nbcnews.com/health/health-news/updated-booster-shot-prevents-majority-covid-hospitalizations-older-ad-rcna62073
    Tenforde MW, Weber ZA, Natarajan K, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19- Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. ePub: 16 December 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e1.htm
    Surie D, DeCuir J, Zhu Y, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19- Associated Hospitalization Among Immunocompetent Adults Aged >= 65 Years - IVY Network, 18 States, September 8-November 30, 2022. MMWR Morb Mortal Wkly Rep. ePub: 16 December 2022 https://www.cdc.gov/mmwr/volumes/71/wr/mm715152e2.htm
  73. 73.0 73.1 McConeghy KW et al. Infections, hospitalizations, and deaths among US nursing home residents with vs without a SARS-CoV-2 vaccine booster. JAMA Netw Open 2022 Dec 7; 5:e2245417 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36477482 Free article https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799266
  74. 74.0 74.1 74.2 Ingram I CDC, FDA Flag Early Signal of Stroke Risk With Bivalent COVID Vaccine. One surveillance system detects potential link in seniors, yet multiple others show none. MedPage Today January 13, 2023 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/102644
  75. 75.0 75.1 Offit Paul A Bivalent Covid-19 Vaccines - A Cautionary Tale. N Engl J Med. 2023. January 11, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36630616 https://www.nejm.org/doi/full/10.1056/NEJMp2215780
  76. 76.0 76.1 Hein I CDC: Bivalent COVID Vaccines Stop Illness From XBB.1.5.
    And Pfizer lab data show better neutralization against latest variants with bivalent shot. MedPage Today January 25, 2023 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/102815
    Link-Gelles R, Ciesla AA, Roper LE et al. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5- Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023. MMWR Morb Mortal Wkly Rep. ePub: 25 January 2023. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36580430 PMCID: PMC9812442 Free PMC article https://www.cdc.gov/mmwr/volumes/72/wr/mm7205e1.htm
  77. 77.0 77.1 Short E Moderna Booster Vaccine Singled Out for Chronic Hives. Chronic spontaneous urticaria more frequent when compared with Pfizer's mRNA vaccine. MedPage Today February 1, 2023 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/102923
    Duperrex O, Tommasini F, Muller YD Incidence of Chronic Spontaneous Urticaria Following Receipt of the COVID-19 Vaccine Booster in Switzerland. JAMA Netw Open. 2023;6(2):e2254298. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36723944 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800873
  78. 78.0 78.1 Tsz Tsun Lai F, Ka Chun Yan V, Ye X Booster vaccination with inactivated whole-virus or mRNA vaccines and COVID-19- related deaths among people with multimorbidity: a cohort study. CMAJ 2023 195(4). Jan 30 https://www.cmaj.ca/content/195/4/E143
  79. 79.0 79.1 Wu N, Joyal-Desmarais K, Ribeiro PAB et al Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. Lancet Respir Med. 2023. Feb 10. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36780914 PMCID: PMC9917454 Free PMC article https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(23)00015-2/fulltext
  80. 80.0 80.1 Jabagi MJ et al Stroke, Myocardial Infarction, and Pulmonary Embolism after Bivalent Booster. N Engl J Med 2023. March 29. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36988584 https://www.nejm.org/doi/full/10.1056/NEJMc2302134
  81. 81.0 81.1 AMA Morning Rounds. April 19, 2023 Amercian Medical Association
    Fiore K Second Omicron Booster Authorized Here's the FDA's latest update on COVID vaccines. MedPage Today April 18, 2023 https://www.medpagetoday.com/infectiousdisease/covid19vaccine/104072
  82. 82.0 82.1 82.2 82.3 Moore JP Why Is One Dose Suddenly Enough for the mRNA COVID Vaccines? FDA and CDC have made yet another questionable decision. MedPage Today. May 2, 2023 https://www.medpagetoday.com/opinion/second-opinions/104295
  83. 83.0 83.1 83.2 Arbel R et al. Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: A retrospective cohort study. Lancet Infect Dis 2023 Apr 13; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37062302 PMCID: PMC10156150 Free PMC article https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00122-6/fulltext
    Lin D-Y et al. Durability of bivalent boosters against omicron subvariants. N Engl J Med 2023 May 11; 388:1818. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37043647 PMCID: PMC10120009 Free PMC article https://www.nejm.org/doi/10.1056/NEJMc2302462
  84. 84.0 84.1 Lane EG et al. Time for resolution of COVID-19 vaccine-related axillary lymphadenopathy and associated factors. AJR Am J Roentgenol 2022 Oct; 219:559. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35583425 https://www.ajronline.org/doi/10.2214/AJR.22.27687
    Mema E et al. Axillary lymphadenopathy after a COVID-19 vaccine booster dose: Time to resolution on ultrasound follow-up and associated factors. AJR Am J Roentgenol 2023 Aug; 221:175. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36883774 https://www.ajronline.org/doi/10.2214/AJR.22.28970
    Mullen LA. Editorial comment: Duration of axillary lymphadenopathy after COVID-19 vaccine booster administration. AJR Am J Roentgenol 2023 Aug; 221:183. PMID: https://www.ncbi.nlm.nih.gov/pubmed/36946901 https://www.ajronline.org/doi/10.2214/AJR.23.29309
  85. 85.0 85.1 AMA Morning Rounds, Oct 4, 2023 American Medical Association
  86. 86.0 86.1 Link-Gelles R, Ciesla AA, Mak J, et al. Early Estimates of Updated 2023-2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, September 2023-January 2024. MMWR Morb Mortal Wkly Rep 2024;73:77-83 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38300853 https://www.cdc.gov/mmwr/volumes/73/wr/mm7304a2.htm
  87. 87.0 87.1 Lu Y et al. Stroke risk after COVID-19 bivalent vaccination among US older adults. JAMA 2024 Mar 19; 331:938. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38502075 PMCID: PMC10951737 (available on 2024-09-19) https://jamanetwork.com/journals/jama/fullarticle/2816237
  88. 88.0 88.1 Moniuszko S. Gualtieri AE New COVID vaccine for 2024, isolation guidelines, free tests and more questions, answered. CBS News. Sept 4, 2024 https://www.cbsnews.com/news/covid-2024-guidelines-isolation-tests-vaccine/